Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model

Acta Ophthalmologica

Volumn 89, Issue 4, 2011, Pages

  Zhang, Rong ^a   Zhang, Haijuan ^a   Xu, Liang ^a   Ma, Ke ^a   Wallrapp, Christine ^b   Jonas, Jost B ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CellMed AG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

glucagon like peptide 1; neuroprotection; optic nerve crush; retina protection

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; DNA MODIFICATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RETINA GANGLION CELL; SUPERIOR COLLICULUS;

ANIMALS; CELL COUNT; CELL SURVIVAL; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; GLUCAGON-LIKE PEPTIDE 1; MICROSPHERES; NERVE CRUSH; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; RETINAL DISEASES; RETINAL GANGLION CELLS; VITREOUS BODY;

EID: 79958081680     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02044.x     Document Type: Article

References (55)

1. AGIS Investigators (2002): The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 134: 499-512.
2. Ahlemeyer B, Junker V, Hühne R, &, Krieglstein J, (2001): Neuroprotective effects of NV-31, a bilobalide-derived compound: evidence for an antioxidative mechanism. Brain Res 890: 338-342. (Pubitemid 32115487)
3. Allcutt D, Berry M, &, Sievers JA, (1984): A qualitative comparison of the reactions of retinal ganglion cells axons to optic nerve crush in neonatal and adult mice. Develop Brain Res 16: 231-240. (Pubitemid 15200283)
4. Brubaker PL, &, Drucker DJ, (2004): Minireview: Glucagon-like peptide regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659. (Pubitemid 38686211)
5. Bush RA, Lei B, Tao W, Raz D, Chan CC, Cox TA, Santos-Muffley M, &, Sieving PA, (2004): Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci 45: 2420-2430. (Pubitemid 38902618)
6. Buys YM, Trope GE, &, Tatton WG, (1995): (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14: 119-126.
7. Cheung ZH, So KF, Lu Q, Yip HK, Wum W, Shan JJ, Pang PK, &, Chen CF, (2002): Enhanced survival and regeneration of axotomized retinal ganglion cells by a mixture of herbal extracts. J Neurotrauma 19: 369-378. (Pubitemid 34246123)
8. Cui Q, Lu Q, So KF, &, Yip HK, (1999): CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest Ophthalmol Vis Sci 40: 760-766. (Pubitemid 29109456)
9. Degenring RF, &, Jonas JB, (2004): Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137: 1142-1143. (Pubitemid 38759374)
10. During MJ, Cao L, Zuzga DS, et al., (2003): Glucagon-like peptide-1 receptor is involved in learning and Neuroprotection. Nat Med 9: 1173-1179. (Pubitemid 37173702)
11. Freeman EE, &, Grosskreutz CL, (2000): The effect of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci 41: 1111-1115. (Pubitemid 30187548)
12. Harmening K, Heile A, Miller M, Johanson CE, Wallrapp C, Brinker T, Silverberg GD, &, Klinge PM, (2009): Microglial downregulation in a double transgenic mouse model associated with early-onset Alzheimer's disease (AD) after intraventricular implantation of alginate encapsulated Glukagon-like-peptide-1 (GLP-1) producing human mesenchymal stem-cells. Cerebrospinal Fluid Res 6 (Suppl 2): S15.
13. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, & Early Manifest Glaucoma Trial Group (2002): Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279. (Pubitemid 36105431)
14. Heile A, Wallrapp C, Klinge P, Samii A, Kassem M, Silverberg G, &, Brinker T, (2009): Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett 463: 176-181.
15. Hoffman W, Kochs E, Werner C, Thomas C, &, Albrecht R, (1991): Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha-2-adrenergic antagonist atipamezole. Anesthesiology 75: 328-332.
16. Jonas JB, (2002): Concentration of intravitreally applicated triamcinolone acetonide in aqueous humour. Brief Report. Br J Ophthalmol 86: 1066. (Pubitemid 34953629)
17. Jonas JB, (2005): Intravitreal triamcinolone acetonide for treatment of intraocular edematous and neovascular diseases. Acta Ophthalmol 83: 645-663. (Pubitemid 41819287)
18. Jonas JB, Kreissig I, &, Degenring RF, (2003): Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 121: 729-730. (Pubitemid 36554480)
19. Jonas JB, Akkoyun I, Kreissig I, &, Degenring RF, (2005a): Diffuse diabetic macular edema treated by intravitreal triamcinolone acetonide. A comparative non-randomised study. Br J Ophthalmol 89: 321-326. (Pubitemid 40327617)
20. Jonas JB, Degenring RF, Kreissig I, Friedemann T, &, Akkoyun I, (2005b): Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye 19: 163-170. (Pubitemid 40326161)
21. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G, &, Spandau UH, (2007): Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol 85: 563-565. (Pubitemid 47163119)
22. Kapin MA, Doshi R, Scatton B, DeSantis LM, &, Chandler ML, (1999): Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. Invest Ophthalmol Vis Sci 40: 1177-1182. (Pubitemid 29211455)
23. Kurokawa T, Katai N, Sbibuki H, Kuroiwa S, Kurimoto Y, Nakayama C, &, Yoshimura N, (1999): BDNF diminishes caspase-2 but not c-jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia. Invest Ophthalmol Vis Sci 40: 3006-3011. (Pubitemid 29521617)
24. Lee EJ, Chen HY, Wu TS, Chen TY, Ayoub IA, &, Maynard KI, (2002): Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. J Neurosci Res 68: 636-645. (Pubitemid 34575630)
25. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, &, Yoles E, (2000): RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 41: 4169-4174.
26. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, &, Melamed S, (2006): Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 124: 520-526.
27. Liebgott T, Miollan M, Berchadsky Y, Drieu K, Culcasi M, &, Pietri S, (2000): Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol 95: 368-377.
28. Luo Y, (2001): Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer's disease. J Alzheimers Dis 3: 401-407. (Pubitemid 32843058)
29. Ma K, Xu L, Zhang H, Zhang S, Pu M, &, Jonas JB, (2009a): Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol 147: 326-331.
30. Ma K, Xu L, Zhan H, Zhang S, Pu M, &, Jonas JB, (2009b): Dosage dependence of the effect of ginkgo biloba on the rat retinal ganglion cell survival after optic nerve crush. Eye 23: 1598-1604.
31. Ma K, Xu L, Zhan H, Zhang S, Pu M, &, Jonas JB, (2010): The effect of ginkgo biloba extract on the rat retinal ganglion cell survival in the optic nerve crush model. Acta Ophthalmol 88: 553-557.
32. Machemer R, Sugita G, &, Tano Y, (1979): Teatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 77: 171-180. (Pubitemid 10072805)
33. Martin KR, Quigley HA, Zack DJ, et al., (2003): Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 44: 4357-4365. (Pubitemid 37186270)
34. Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz JC, Adamsons I, & EGPS Group (2007): Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 144: 266-275.
35. Misantone LJ, Gershenbaum M, &, Murray M, (1984): Viability of retinal ganglion cells after optic nerve crush in adult rats. J Neurocytol 13: 449-465. (Pubitemid 14094362)
36. Mittag TW, Danias J, Poborenec G, Yuan HM, Burakgazi E, Chalmers-Redman R, Podos SM, &, Tatton WG, (2000): Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41: 3451-3459.
37. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, &, Greig NH, (2007): Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203: 293-301. (Pubitemid 46157226)
38. Pu M, &, Berson DM, (1997): A method for fast and stable intracellular staining of retinal ganglion cells. J Neurosci Method 41: 45-51.
39. Schindler RH, Chandler DB, Thresher R, &, Machemer R, (1982): The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93: 415-417. (Pubitemid 12143608)
40. Sieving P A, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, &, Bush RA, (2006): Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 103: 3896-3901. (Pubitemid 43376652)
41. Solberg Y, Rosner M, Turetz J, &, Belkin M, (1997): MK-801 has neuroporotective and antiproliferative effects in retinal laser injury. Invest Ophthalmol Vis Sci 38: 1380-1389. (Pubitemid 27278557)
42. Soulié C, Nicole A, Christen Y, &, Ceballos-Picot I, (2002): The Ginkgo biloba extract EGb 761 increases viability of hnt human neurons in culture and affectsthe expression of genes implicated in the stress response. Cell Mol Biol (Noisy-le-grand) 48: 641-646.
43. Spandau UH, Ihloff AK, &, Jonas JB, (2006): Intravitreal bevacizumab treatment of macular edema due to central retinal vein occlusion. Acta Ophthalmol 84: 555-556. (Pubitemid 44109048)
44. Tao W, Wen R, Goddard MB, et al., (2002): Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43: 3292-3298.
45. Thanos CG, Bell WJ, O′Rourke P, Kauper K, Sherman S, Stabila P, &, Tao W, (2004): Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng 10: 1617-1622. (Pubitemid 40054203)
46. Wein FB, &, Levin LA, (2002): Current understanding of neuroprotection in glaucoma. Curr Opin Ophthalmol 13: 61-67. (Pubitemid 34261263)
47. Wen R, Cheng T, Li Y, Cao W, &, Steinberg R, (1996): 2-Adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 16: 5986-5992. (Pubitemid 26313974)
48. Yasuyoshi H, Kashii S, Zhang S, et al., (2000): Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest Ophthalmol Vis Sci 41: 2273-2278. (Pubitemid 30451003)
49. Yoles E, &, Schwartz M, (1998a): Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol 42: 367-372. (Pubitemid 28092777)
50. Yoles E, &, Schwartz M, (1998b): Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 116: 906-910. (Pubitemid 28554781)
51. Yoles E, Wheeler LA, &, Schwartz M, (1999): α2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 40: 65-73. (Pubitemid 29029573)
52. Yücel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, &, Weinreb RN, (2006): Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 124: 217-225. (Pubitemid 43247073)
53. Zhang R, Ma K, Xu L, Wallrapp C, &, Jonas JB, (2010): Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber. Acta Ophthalmol 88: e348-349.
54. Zhang R, Zhang H, Ma K, Xu L, Wallrapp C, &, Jonas JB, (in press): Intravitreal cell-based production of glucagon-like peptide-1. Retina.
55. Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, &, Ng YS, (2007): Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 48: 1212-1218. (Pubitemid 351261416)